|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/395 | |
| A61K 47/48 | |||
| A61P 37/00 | |||
| C07K 16/24 |
| (11) | Number of the document | 1687026 |
| (13) | Kind of document | T |
| (96) | European patent application number | 04798568.4 |
| Date of filing the European patent application | 2004-11-16 | |
| (97) | Date of publication of the European application | 2006-08-09 |
| (45) | Date of publication and mention of the grant of the patent | 2008-05-14 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/GB2004/004850 |
| Date | 2004-11-16 |
| (87) | Number | WO 2005/051422 |
| Date | 2005-06-09 |
| (30) | Number | Date | Country code |
| 0327181 | 2003-11-21 | GB | |
| 0417115 | 2004-07-30 | GB |
| (72) |
CHRISTIE, Mark Ian, Celltech R & D Limited, GB
MEAD, Richard James, Celltech R & D Limited, GB
ROBINSON, Martyn Kim, Celltech R & D Limited, GB
RAPECKI, Stephen Edward, Celltech R & D Limited, GB
|
| (73) |
UCB Pharma, S.A.,
Allée de La Recherche 60, 1070 Brussels,
BE
|
| (54) | METHOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS BY INHIBITING IL-17 ACTIVITY |
| METHOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS BY INHIBITING IL-17 ACTIVITY |